Literature DB >> 32033135

Reply to Comment on "Kadomoto, S. et al. Tumor-Associated Macrophages Induce Migration of Renal Cell Carcinoma Cells via Activation of the CCL20-CCR6 Axis" Cancers 2020 12, 89.

Suguru Kadomoto1, Kouji Izumi1, Kaoru Hiratsuka1, Taito Nakano1, Renato Naito1, Tomoyuki Makino1, Hiroaki Iwamoto1, Hiroshi Yaegashi1, Kazuyoshi Shigehara1, Yoshifumi Kadono1, Hiroki Nakata2, Yohei Saito3, Kyoko Nakagawa-Goto3, Atsushi Mizokami1.   

Abstract

We appreciate Zins and Abraham [1] commenting on our paper studying the role of the CCL20-CCR6 axis on renal cell carcinoma (RCC) cells [2]. As they pointed out, our study has certain limitations. Although M1- and M2-types cannot be separated clearly and a consecutive change of character might exist between them, it has been reported that plural specific markers express on M1- and M2-types. Unfortunately, a definite difference between M1 and M2 macrophages was not confirmed in our study. For more differentiation, multiple stimulations, such as suggested in the comments of Zins and Abraham, might be needed. Hence, we needed to expediently use "M1-like" and "M2-like" to mention specific status of these macrophage-like cells. Meanwhile, CCL20 expression levels of M2-like-THP-1 cells co-cultured with RCC cells were dramatically increased compared with parental THP-1 cells, indicating that certain stimulations within the tumor microenvironment rather than theoretical stimulations make macrophages differentiated; however, further studies are needed to clarify this mechanism using a more appropriate co-culture system mimicking the tumor microenvironment. Immunohistochemistry of CCL20 and M2 markers will help to better understand the role of tissue infiltrating macrophages, even tissue CD68 staining intensity itself was reported to correlate with prognosis of RCC patients [3]. [...].

Entities:  

Year:  2020        PMID: 32033135      PMCID: PMC7073159          DOI: 10.3390/cancers12020354

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


We appreciate Zins and Abraham [1] commenting on our paper studying the role of the CCL20-CCR6 axis on renal cell carcinoma (RCC) cells [2]. As they pointed out, our study has certain limitations. Although M1- and M2-types cannot be separated clearly and a consecutive change of character might exist between them, it has been reported that plural specific markers express on M1- and M2-types. Unfortunately, a definite difference between M1 and M2 macrophages was not confirmed in our study. For more differentiation, multiple stimulations, such as suggested in the comments of Zins and Abraham, might be needed. Hence, we needed to expediently use “M1-like” and “M2-like” to mention specific status of these macrophage-like cells. Meanwhile, CCL20 expression levels of M2-like-THP-1 cells co-cultured with RCC cells were dramatically increased compared with parental THP-1 cells, indicating that certain stimulations within the tumor microenvironment rather than theoretical stimulations make macrophages differentiated; however, further studies are needed to clarify this mechanism using a more appropriate co-culture system mimicking the tumor microenvironment. Immunohistochemistry of CCL20 and M2 markers will help to better understand the role of tissue infiltrating macrophages, even tissue CD68 staining intensity itself was reported to correlate with prognosis of RCC patients [3]. As, CCL20, a secreted protein, is distributed diffusely in tissue, the identification of cells secreting CCL20 might be challenging. Instead of CCL20 staining, we performed CCR6 staining to depict the functional effect of CCL20. We agree that distinct staining of M1 and M2 markers in RCC tissue with increased sample number and the use of patient-derived M2 macrophages from RCC patients will clarify the role of the CCL20-CCR6 axis on RCC progression.
  3 in total

1.  Pathological significance and prognostic roles of densities of CD57+ cells, CD68+ cells, and mast cells, and their ratios in clear cell renal cell carcinoma.

Authors:  Hiromi Nakanishi; Yasuyoshi Miyata; Yasushi Mochizuki; Takuji Yasuda; Yuichiro Nakamura; Kyohei Araki; Yuji Sagara; Tomohiro Matsuo; Kojiro Ohba; Hideki Sakai
Journal:  Hum Pathol       Date:  2018-05-19       Impact factor: 3.466

2.  Comment on:Kadomoto, S. et al. "Tumor-Associated Macrophages Induce Migration of Renal Cell Carcinoma Cells via Activation of the CCL20-CCR6 Axis" Cancers 2020, 12, 89.

Authors:  Karin Zins; Dietmar Abraham
Journal:  Cancers (Basel)       Date:  2020-02-03       Impact factor: 6.639

3.  Tumor-Associated Macrophages Induce Migration of Renal Cell Carcinoma Cells via Activation of the CCL20-CCR6 Axis.

Authors:  Suguru Kadomoto; Kouji Izumi; Kaoru Hiratsuka; Taito Nakano; Renato Naito; Tomoyuki Makino; Hiroaki Iwamoto; Hiroshi Yaegashi; Kazuyoshi Shigehara; Yoshifumi Kadono; Hiroki Nakata; Yohei Saito; Kyoko Nakagawa-Goto; Atsushi Mizokami
Journal:  Cancers (Basel)       Date:  2019-12-30       Impact factor: 6.639

  3 in total
  2 in total

1.  Tumor-associated neutrophils activated by tumor-derived CCL20 (C-C motif chemokine ligand 20) promote T cell immunosuppression via programmed death-ligand 1 (PD-L1) in breast cancer.

Authors:  Louis Boafo Kwantwi; Shujing Wang; Wenjun Zhang; Weidong Peng; Zeyu Cai; Youjing Sheng; Han Xiao; Xian Wang; Qiang Wu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

Review 2.  Multifaceted roles of CCL20 (C-C motif chemokine ligand 20): mechanisms and communication networks in breast cancer progression.

Authors:  Louis Boafo Kwantwi; Shujing Wang; Youjing Sheng; Qiang Wu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.